EGFR and non-small cell lung carcinoma: The therapeutic landscape for advanced non-small cell lung cancer (NSCLC) harboring common EGFR mutations - namely exon 19 deletions (ex19del) and L858R substitutions - has significantly evolved, with osimertinib becoming the global first-line standard following the pivotal FLAURA trial.